Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...
Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
Everyday Health on MSN
How to plan for successful home SCIg self-administration for primary immunodeficiency
Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...
Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...
New one-dose treatment edits a gene in the liver, disabling the ANGPTL3 protein and significantly lowers cholesterol.
Scotland has approved its first CLDN18.2-targeted therapy for advanced gastric and GEJ cancer, expanding options for patients ...
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody ...
Takeda (NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less ...
Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...
Bio-Sourcing and Zerion Pharma have obtained a €1.3 million EU grant reward under the Eurostars program to advance an orally administered anti‑HER2, antibody Trastuzimab, for treatment of breast ...
Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...
Cervical lymphadenopathy presents a shared anatomic challenge for clinicians, yet it serves as the divergent starting point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results